---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020786"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:03:13.099766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q1 net loss $15.6M; cash $57.4M; PKU program gets FDA/EMA designations

## Summary
- Net loss of $15.6M ($0.23 per share) vs $15.7M in Q1 2022; revenue flat at $0.2M.
- Cash, equivalents and short-term investments $57.4M; runway into H2 2024.
- FDA granted Rare Pediatric and Orphan Drug Designations for SYNB1934 in PKU; EMA also granted orphan designation.
- Phase 3 trial (Synpheny-3) for SYNB1934 in PKU on track to start H1 2023.
- SYNB1353 for HCU advancing to Phase 2; preclinical pipeline progressing.

## SEC filing metadata
- accession: 0000950170-23-020786
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017023020786/0000950170-23-020786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017023020786/sybx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020786
- JSON: https://secwatch.observer/filing/0000950170-23-020786.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020786.txt

## Key facts
- Earnings Releases
  SYNLOGIC, INC. reported first quarter ended March 31, 2023 results: revenue $0.2 million, net income consolidated net loss of $15.6 million, EPS $0.23 per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $0.2 million
  - Net income: consolidated net loss of $15.6 million
  - EPS: $0.23 per share
  - Result: reported results
  source text: partnerships Page 1 of 4 First Quarter 2023 Financial Results As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ended March 31, 2023 and March 31, 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017023020786/0000950170-23-020786-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.